Skip to main content
. 2019 Nov 22;9:17358. doi: 10.1038/s41598-019-53711-3

Figure 2.

Figure 2

Changes in ctDNA levels in mCRC patients treated with second-line chemotherapy. ctDNA analysis at baseline, 2 weeks and 8 weeks after initiation of second-line chemotherapy in all the patients (A) and the patients with PD and SD or PR (B). Treatment responses were evaluated by CT images.